Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ampio Pharmaceuticals has got Notice of Allowance (NoA) for its two patent applications on Zertane combinations with erectile dysfunction (ED) in Canada .
Subscribe to our email newsletter
The NoA includes claims directed to the use of Zertane with a class of drugs called phosphodiesterase type 5 (PDE5) inhibitors commonly used for the treatment of ED to address concurrent premature ejaculation (PE) and ED.
Additionally, the allowed claims also include composition of matter claims, such as claims directed to a pharmaceutical composition or a kit containing Zertane and a PDE5 inhibitor.